尿酸升高伊诺辛对帕金森病早期进展的影响:SURE-PD3随机临床试验
, Michael A Schwarzschild1,2, Alberto Ascherio3
1Mass General Institute for Neurodegenerative Disease, Boston, Massachusetts.
JAMA
|September 14, 2021
概括
在临床试验中,因诺辛治疗没有减缓帕金森病的进展. 这项研究表明,伊诺辛不是早期帕金森病的有效治疗方法.
科学领域:
- 神经科学
- 临床神经学
- 药理学
背景情况:
- 尿酸升正在作为帕金森病 (PD) 的疾病修饰策略进行研究.
- 一致的生物,流行病学和临床数据支持尿酸在PD中的潜在作用.
- 之前的研究表明尿酸含量与PD之间存在联系,
研究的目的:
- 评估持续的尿酸升高治疗是否会减缓早期帕金森病的进展.
- 确定伊诺辛在早期患病患者中的疗效和安全性.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的第三期试验.
- 298名早期的PD患者接受了口服伊诺辛或安慰剂,长达2年.
- 主要结果:运动障碍学会统一帕金森病评分表 (MDS- UPDRS) 评分的变化.
主要成果:
- 在减缓PD临床进展方面,伊诺辛治疗与安慰剂没有显著差异 (MDS- UPDRS得分).
- 在 inosine 组中,血清尿酸水平持续升高.
- 在 inosine 组中观察到的严重不良事件较少,但结石更为频繁.
结论:
- 在早期帕金森病的临床疾病进展缓慢方面,伊诺辛治疗没有显著的差异.
- 这些发现不支持使用伊诺辛作为早期PD的治疗剂.
- 可能需要进一步的研究来探索PD中的其他尿酸调节策略.
更多相关视频
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.0K
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.7K
相关概念视频
Parkinson's Disease: Treatment
447
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
447
Parkinson's Disease: Overview
857
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
857
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
33
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
33
Neural Regulation
40.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.6K
